Patheon: Expediting supply of Ph I trial drugs can cut pharma costs

Patheon: Expediting supply of Ph I trial drugs can cut pharma costs

Patheon has sliced four weeks off its Quick-to-Clinic service saying speedier supply of materials for first in human trials increases pharma’s return on investment.

The contract development and manufacturing organisation (CDMO) launched its Quick-to-Clinic service at a facility in Whitby, Ontario in 2008, providing pharma companies with a rapid-response means of making solid dosage forms for early phase clinical trial.

Patheon has since expanded the service in order to offer it from sites in Cincinnati, Ohio, Milton Park, UK, and Tilburg, the Netherlands, and last week announced a further update which the firm says accelerates the production of Phase I material across six dosage forms.

“In the previous Quick to Clinic we marketed a four month timeline which has been reduced to 12 weeks,” a spokesman from the CDMO told Outsourcing-Pharma.com.

“All pharma and biotech companies recognise the need to accelerate drug development, either to progress to next milestone/clinical phase or indeed to kill the compound altogether,” he continued, adding all firms - whether emerging or large pharma - are looking to make drug development more efficient and improve their return on investment.

“Availability of cGMP API is typically on the critical path so anything that can be done in getting drug product to First in Humans more quickly is always of interest to the industry.”

The 12 week timeline focuses on BCS Class I molecules – drugs with high permeability and high solubility - in 6 of available dosage forms, with softgels the latest addition to API in Capsule, Blend in Capsule, API in bottle, Blend in bottle, and Oral Liquid. “Each project will be evaluated and custom programme developed as needed to fit the project goals and the molecules characteristics,” we were told.

Patheon merged with the pharmaceutical product segment of Royal DSM to form DPx Holdings earlier this year, though we were told this updated service was not related to the $2.65bn (€1.9bn) deal.

Related News

FT conference in London on Tuesday. George Freeman outlined plans to accelereate drug development process

UK Hospitals to play part in Gov efforts to speed clinical trial process

Irix Pharmaceutical facility in Greenvill to be acquired by Patheon in takeover deal

Patheon: Irix deal about US and Canadian customer demand for local APIs; all staff to be retained

Strategic partnerships driving consolidation of CMO industry

Strategic partnerships driving consolidation of CDMO industry, says report

Recipharm: 'Client investment gives us competitive edge in CDMO space'

Recipharm: 'Client investment gives us competitive edge in CDMO space'

Outsourcing up for GMP APIs as Onyx completes manufacturing deal

Outsourcing up for GMP APIs as Onyx completes manufacturing deal

Capsugel: 'More than a capsule maker,' as it wins manufacturing contract

'No longer simply a capsule provider' - Capsugel wins oral peptide contract

Patheon launches small-scale filling service

Patheon's Swindon, UK plant was earmarked for closure in 2012

Shift to CMO strategic alliances key to UK plant turnaround, says Patheon